The company that today is called Prostatype Genomics AB was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm, Sweden) in order to transfer the research results of the research group into clinical reality. To date, 15 years of research work in the area of prostate cancer genomics has resulted in the development of a market-ready product, providing decision support for treatment selection of prostate cancer patients: The Prostatype® Test System.

The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in prostate cancer.